Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cortisone Treatment for the Prevention of Postoperative Pancreatitis and Pancreatitis-induced Complications After Pancreaticoduodenectomy and Distal Pancreatic Resection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01460615
Recruitment Status : Completed
First Posted : October 27, 2011
Last Update Posted : November 29, 2018
Sponsor:
Information provided by (Responsible Party):
Tampere University Hospital

Brief Summary:
The purpose of this randomized, placebo-controlled trial is to investigate whether postoperative pancreatitis and other immediate complications after pancreaticoduodenectomy or distal pancreatic resection may be reduced with cortisone treatment. Treatment is administered to high risk patients (defined by high amount of acinar cells in the cut edge of pancreas).

Condition or disease Intervention/treatment Phase
Postoperative Complications Postoperative Pancreatitis Drug: Hydrocortisone Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Study Start Date : February 2011
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017





Primary Outcome Measures :
  1. Postoperative overall complications of pancreatic resection [ Time Frame: within the first 30 days after surgery ]
    e.g. Postoperative pancreatic fistula, delayed gastric emptying, postpancreatectomy hemorrhage, biliary fistula, wound infection, postoperative pancreatitis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Pancreaticoduodenectomy and distal pancreatectomy patients in Tampere University Hospital

Exclusion Criteria:

  • Patients with an ongoing cortisone treatment
  • Cefuroxime allergy
  • Chronic pancreatitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01460615


Locations
Layout table for location information
Finland
Tampere University Hospital
Tampere, Finland, 33520
Sponsors and Collaborators
Tampere University Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Tampere University Hospital
ClinicalTrials.gov Identifier: NCT01460615    
Other Study ID Numbers: R11009M
First Posted: October 27, 2011    Key Record Dates
Last Update Posted: November 29, 2018
Last Verified: October 2011
Keywords provided by Tampere University Hospital:
Postoperative pancreatitis
Postoperative complications
Delayed gastric emptying
Leakage
Fistula
Acinar cell
Risk patient
Pancreaticoduodenectomy
Whipple
Cortisone
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis
Postoperative Complications
Pancreatic Diseases
Digestive System Diseases
Pathologic Processes
Hydrocortisone
Anti-Inflammatory Agents